Subcutaneous Herceptin approved in EU

 
• By Lucie Ellis-Taitt
  
Generate a summary of this article
Listen to this article
Beta

San Diego-based Halozyme Therapeutics has been granted European marketing authorization from the European Commission for a subcutaneous formulation of Roche's Herceptin (trastuzumab), which contains Halozyme's recombinant human hyaluronidase (rHuPH20). The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of the extension in early July 2013 (scripintelligence.com, 1 July 2013). The approval applies to all lines of treatment for women with HER2-positive breast cancer, but does not apply to gastric cancer labeling for intravenous Herceptin. The EC's decision was based on data from the HannaH study.

San Diego-based Halozyme Therapeutics has been granted European marketing authorization from the European Commission for a subcutaneous formulation of Roche's Herceptin (trastuzumab), which contains Halozyme's recombinant human hyaluronidase (rHuPH20). The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of the extension in early July 2013 (scripintelligence.com, 1 July 2013). The approval applies to all lines of treatment for women with HER2-positive breast cancer, but does not apply to gastric cancer labeling for intravenous Herceptin. The EC's decision was based on data from the HannaH study.

Subcutaneous administration reduces treatment from a 30- to 90-minute IV infusion to an injection given in just a few minutes,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

 
• By Xu Hu

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer

The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.